IXICO has secured one of its biggest contracts yet, worth $7m over seven years for clinical trial services. The award supports our investment thesis and financial forecasts, reflecting strong growth through the expansion into new indications, new markets and bigger contracts. IXICO is also well placed to capitalise on the burgeoning use of digital technologies in disease management. Using a DCF, we value IXICO at £10.7m or 63p/share.
